Spots Global Cancer Trial Database for glofitamab
Every month we try and update this database with for glofitamab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma | NCT06047080 | Large B-Cell Ly... | Glofitamab Polatuzumab ved... Rituximab Cyclophosphamid... Doxorubicin Prednisone | 18 Years - 80 Years | Hoffmann-La Roche | |
| A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | NCT04408638 | Diffuse Large B... | Obinutuzumab Glofitamab Rituxumab Tocilizumab Gemcitabine Oxaliplatin | 18 Years - | Hoffmann-La Roche | |
| Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma | NCT05861050 | Blastoid Varian... Mantle Cell Lym... Pleomorphic Var... | Biopsy Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Glofitamab Lenalidomide Obinutuzumab Positron Emissi... Venetoclax | 18 Years - 80 Years | City of Hope Medical Center | |
| A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma | NCT04313608 | B-cell Lymphoma | Glofitamab Gemcitabine Oxaliplatin Mosunetuzumab Obinutuzumab Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma | NCT05800366 | Lymphoma Lymphoma, Large... | Glofitamab Polatuzumab Rituximab Doxorubicin Hyd... Cyclophosphamid... Prednisone | 18 Years - | Dana-Farber Cancer Institute | |
| A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | NCT03075696 | Non-Hodgkin's L... | Glofitamab Obinutuzumab Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma | NCT05783596 | Follicular Lymp... Marginal Zone L... Indolent Non-ho... | Obinutuzumab Glofitamab | 18 Years - | Dana-Farber Cancer Institute | |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | NCT05219513 | Lymphoma, Non-H... | RO7443904 Glofitamab Obinutuzumab Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL) | NCT06050694 | Diffuse Large B... | glofitamab | 18 Years - | University Health Network, Toronto | |
| A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation | NCT06043674 | Chronic Lymphoc... Richter's Trans... | Glofitamab Obinutuzumab Polatuzumab Ved... Atezolizumab Tocilizumab | 18 Years - | Dana-Farber Cancer Institute | |
| A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma | NCT04980222 | Lymphoma | Glofitamab Tocilizumab Doxorubicin Vincristine Prednisone Rituximab Cyclophosphamid... | 18 Years - | Hoffmann-La Roche | |
| A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL | NCT03467373 | B-Cell Lymphoma Non-Hodgkin Lym... | Glofitamab Obinutuzumab (G... Rituximab (R) Tocilizumab Cyclophosphamid... Doxorubicin Vincristine Prednisone Polatuzumab ved... | 18 Years - | Hoffmann-La Roche | |
| A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab as a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma | NCT06071871 | Large B-cell Ly... | Glofitamab Polatuzumab ved... Obinutuzumab | 18 Years - | University College, London | |
| A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma | NCT06213311 | B Cell Lymphoma | Glofitamab Obinutuzumab Axi-cel | 18 Years - | M.D. Anderson Cancer Center | |
| A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma | NCT05533775 | Mature B-Cell N... | Obinutuzumab Glofitamab Rituximab Ifosfamide Carboplatin Etoposide Tocilizumab | 6 Months - 30 Years | Hoffmann-La Roche | |
| A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | NCT04408638 | Diffuse Large B... | Obinutuzumab Glofitamab Rituxumab Tocilizumab Gemcitabine Oxaliplatin | 18 Years - | Hoffmann-La Roche | |
| Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | NCT06054776 | Mantle Cell Lym... | Acalabrutinib Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Echocardiograph... Glofitamab Multigated Acqu... Obinutuzumab Positron Emissi... | 18 Years - | City of Hope Medical Center | |
| A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma | NCT04980222 | Lymphoma | Glofitamab Tocilizumab Doxorubicin Vincristine Prednisone Rituximab Cyclophosphamid... | 18 Years - | Hoffmann-La Roche | |
| An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma | NCT06047080 | Large B-Cell Ly... | Glofitamab Polatuzumab ved... Rituximab Cyclophosphamid... Doxorubicin Prednisone | 18 Years - 80 Years | Hoffmann-La Roche | |
| Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma | NCT05861050 | Blastoid Varian... Mantle Cell Lym... Pleomorphic Var... | Biopsy Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Glofitamab Lenalidomide Obinutuzumab Positron Emissi... Venetoclax | 18 Years - 80 Years | City of Hope Medical Center | |
| Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma | NCT06357676 | Mantle Cell Lym... | Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Echocardiograph... FDG-Positron Em... Glofitamab Ibrutinib Magnetic Resona... Obinutuzumab | 18 Years - | OHSU Knight Cancer Institute | |
| A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) | NCT04970901 | B-Cell Non-Hodg... Relapsed B-Cell... Refractory B-Ce... | Loncastuximab T... Polatuzumab Ved... Glofitamab Mosunetuzumab Obinutuzumab | 18 Years - | ADC Therapeutics S.A. | |
| Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma | NCT06252675 | Mantle Cell Lym... | Obinutuzumab Glofitamab Pirtobrutinib Tumor Imaging Biospecimen Col... ClonoSeq Assay Bone Marrow Bio... | 18 Years - | University of California, San Francisco | |
| An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | NCT03533283 | Non-Hodgkins Ly... | Glofitamab Atezolizumab Obinutuzumab Tocilizumab Polatuzumab Ved... 89Zr-Df-IAB22M2... | 18 Years - | Hoffmann-La Roche | |
| A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) | NCT04970901 | B-Cell Non-Hodg... Relapsed B-Cell... Refractory B-Ce... | Loncastuximab T... Polatuzumab Ved... Glofitamab Mosunetuzumab Obinutuzumab | 18 Years - | ADC Therapeutics S.A. | |
| A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | NCT03075696 | Non-Hodgkin's L... | Glofitamab Obinutuzumab Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of RO7227166 in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | NCT04077723 | Lymphoma, Non-H... | RO7227166 Obinutuzumab Glofitamab Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma | NCT06213311 | B Cell Lymphoma | Glofitamab Obinutuzumab Axi-cel | 18 Years - | M.D. Anderson Cancer Center | |
| A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) | NCT04970901 | B-Cell Non-Hodg... Relapsed B-Cell... Refractory B-Ce... | Loncastuximab T... Polatuzumab Ved... Glofitamab Mosunetuzumab Obinutuzumab | 18 Years - | ADC Therapeutics S.A. | |
| Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma | NCT05861050 | Blastoid Varian... Mantle Cell Lym... Pleomorphic Var... | Biopsy Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Glofitamab Lenalidomide Obinutuzumab Positron Emissi... Venetoclax | 18 Years - 80 Years | City of Hope Medical Center | |
| A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma | NCT04980222 | Lymphoma | Glofitamab Tocilizumab Doxorubicin Vincristine Prednisone Rituximab Cyclophosphamid... | 18 Years - | Hoffmann-La Roche | |
| A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma | NCT06084936 | Lymphoma | Obinutuzumab Glofitamab Rituximab Bendamustine Lenalidomide Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP | NCT05798156 | Lymphoma, Large... | Glofitamab Rituximab Obinutuzumab Polatuzumab ved... | 61 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma | NCT06084936 | Lymphoma | Obinutuzumab Glofitamab Rituximab Bendamustine Lenalidomide Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma | NCT06252675 | Mantle Cell Lym... | Obinutuzumab Glofitamab Pirtobrutinib Tumor Imaging Biospecimen Col... ClonoSeq Assay Bone Marrow Bio... | 18 Years - | University of California, San Francisco | |
| Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma | NCT04161248 | Lymphoma, B-Cel... | Venetoclax Rituximab Injec... Rituximab SC Gemcitabine Dexamethasone Cisplatin Glofitamab Tafasitamab | 16 Years - 65 Years | Canadian Cancer Trials Group | |
| Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma | NCT05783596 | Follicular Lymp... Marginal Zone L... Indolent Non-ho... | Obinutuzumab Glofitamab | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma | NCT06192888 | Mantle Cell Lym... MCL | Glofitamab Obinutuzumab Lenalidomide | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | NCT04408638 | Diffuse Large B... | Obinutuzumab Glofitamab Rituxumab Tocilizumab Gemcitabine Oxaliplatin | 18 Years - | Hoffmann-La Roche |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
